Company recognized for innovation, leadership and workplace culture
SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Sama, delivering data certainty for enterprise AI through tech-enabled annotation, validation and evaluation services, today announced multiple international honors, awarding Sama for its workplace culture, company growth, technology innovation and business leadership.
At the 2025 Africa Digital Economy Awards, Sama was named Most Innovative BPO Provider of the Year, recognized for its proprietary platform and human-in-the-loop (HITL) approach that powers complex AI model training in autonomous vehicles, agriculture, retail and healthcare. The platform combines ML-assisted tools with expert annotators to deliver industry-leading accuracy and efficiency from the first data set.
Sama Vice President of Global Service Delivery, Annepeace Alwala, was also recognized at the Digital Economy Awards, winning Digital Woman of the Year award for her leadership in scaling Sama’s impact in East Africa and advancing opportunities for women in technology. Alwala oversees a workforce of more than 3,000 employees across Kenya and Uganda and has helped drive milestones including achieving B Corp certification and forging national partnerships to expand youth employment in the digital economy.
In addition, Sama received the Impact Sourcing Honor from Elevate Group, which recognizes companies that create economic opportunities for people with the greatest barriers to work. The award highlights Sama’s proven impact sourcing model, through which the company has helped nearly 70,000 people lift themselves out of poverty via formal digital-economy employment.
Sama was also named to the 2025 Global Inspiring Workplaces list, following earlier recognition among the top three Inspiring Workplaces in the Middle East and Africa. This global accolade highlights Sama’s investments in wellbeing, inclusion and professional growth that have created measurable outcomes for employees and customers.
“Our mission is to prove that responsible AI delivers enterprise results and social impact,” said Wendy Gonzalez, CEO of Sama. “These various awards validate the systems we’ve built and our world class team. From our inception, Sama has remained committed to delivering industry-leading AI solutions alongside life-changing opportunities for individuals who previously had no access into the digital economy. We are honored to be recognized for these efforts.”
Sama delivers data certainty for enterprise AI through tech-enabled annotation, validation and evaluation services. By combining advanced platforms with expert human judgment, Sama helps some of the world’s largest companies, including 30% of the Fortune 50, move AI models from development to production with confidence. With thousands of skilled data professionals and industry-leading quality guarantees, Sama tackles the critical challenge that over 63% of AI models fail to reach production due to poor data quality.
Founded in 2008, Sama has delivered more than 40 billion data points and created employment opportunities that have helped over 70,000 people lift themselves out of poverty. As a certified B Corporation, Sama is committed to advancing both technological innovation and social impact. Learn more at www.sama.com.
TAMPA, FL / ACCESS Newswire / September 30, 2025 / Wellgistics Health, Inc. (“Wellgistics Health” or the “Company”) (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced a strategic collaboration with TheracosBio, the manufacturer of Brenzavvy® (bexagliflozin), to make diabetes medications more affordable and accessible across the U.S. healthcare system.
The joint effort leverages Wellgistics Health’s “maker-to-taker” platform – a direct pipeline that connects manufacturers to pharmacies and patients while bypassing costly intermediaries. With over 6,500 independent and chain pharmacies in its national network, Wellgistics Health will expand access to Brenzavvy through both traditional retail and direct-to-patient delivery models.
Key Benefits of the Collaboration
Expanded Access – Brenzavvy will be made available through the Wellgistics Health network of 6,500+ independent pharmacies, as well as participating chain pharmacies, reaching patients nationwide.
Affordability – By eliminating middlemen, this initiative is expected to lower costs to levels often below typical insurance copayments, easing patient cost burdens and increasing adherence.
Pharmacist Empowerment – Participating pharmacies will provide patient counseling, adherence support, and care coordination.
AI & Technology Integration – The Wellgistics Tech & Hub platform, powered by AI-driven modules, will streamline eligibility checks, claims adjudication, adherence tracking, and reporting.
Addressing an Urgent Need
Type 2 diabetes affects over 37 million Americans and costs the U.S. an estimated $327 billion annually. Yet only one in eight eligible adults receives an SGLT-2 inhibitor, largely due to out-of-pocket costs that can exceed $500 per month.
Brenzavvy, a once-daily oral treatment, offers a cost-effective option within the SGLT-2 inhibitor class, designed to improve glycemic control in adults when used in conjunction with diet and exercise.
Executive Commentary
“Millions of Americans with type 2 diabetes still face affordability and access barriers at the pharmacy counter,” said Brian Connelly, CEO of TheracosBio. “Through Wellgistics Health’s streamlined approach, we are expanding access to Brenzavvy, helping patients afford their medications while empowering pharmacists to deliver meaningful care.”
“Direct-to-patient affordability and access programs are a cornerstone of Wellgistics Health’s mission,” said Brian Norton, CEO of Wellgistics Health. “We are pioneering innovative models designed to not only expand patient access but also bring new levels of transparency and affordability to the healthcare system. By leveraging our technology-enabled platform and our national network of independent and chain pharmacies, we are striving to ensure powerful therapies like Brenzavvy are delivered efficiently, responsibly, and at a cost that patients can sustain.”
Everyone Wins
Patients pay less and gain greater access to a vital class of diabetes medications.
Pharmacies receive fair compensation and tools to enhance patient care.
Employers and Health Plans see expedited and transparent savings without waiting for rebate reconciliations.
Manufacturers gain a direct, efficient channel to reach patients and expand therapy adoption.
Execution Roadmap
Brenzavvy will be integrated into the Wellgistics Tech & Hub and Distribution platform beginning in Q4 2025, enabling immediate patient onboarding through affiliated pharmacies and direct-to-patient channels.
Q4 2025 rollout positions WGRX for near-term revenue impact.
This collaboration underscores Wellgistics Health’s aim to be a disruptive force in pharmaceutical distribution, redefining how therapies move from manufacturer to patient with transparency, affordability, and scale.
About TheracosBio
TheracosBio is a biopharmaceutical company dedicated to developing and commercializing therapies that address unmet needs in chronic disease management. Its lead product, Brenzavvy, was developed to provide an effective, affordable SGLT-2 inhibitor option for adults with type 2 diabetes.
Wellgistics Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.
Skyline Corporate Communications Group, LLC Scott Powell, President 1177 Avenue of the Americas, 5th Floor New York, NY 10036 Office: (646) 893-5835 Email: info@skylineccg.com
All-cash purchase price of approximately $700,000;
Eventdex serves 60+ customers; generated ~$750K in 2024 revenue and ~$500K year-to-date 2025.
Combination unifies Map D’s floor mapping with Eventdex’s registration and badge printing-and fast-tracks Nextech3D.ai’s blockchain ticketing roadmap.
NEW YORK CITY, NY AND TORONTO, ON / ACCESS Newswire / September 30, 2025 / Nextech3D.ai (CSE:NTAR)(OTCQX:NEXCF)(FSE:EP2) (“Nextech3D.ai” or the “Company”), an AI-first event-technology and 3D solutions provider, today announced it has signed a binding letter of intent (LOI) to acquire Eventdex, a registration and badge-printing software company serving 60+ customers with approximately $750,000 in revenue for 2024 and approximately $500,000 year-to-date 2025.
Under the LOI, the purchase price is approximately $700,000, payable entirely in cash subject to customary adjustments. A 30-day due diligence period has commenced; subject to satisfactory completion of diligence, negotiation of definitive agreements, and customary approvals, the parties expect to proceed to closing on or before October 19th, 2025.
Accelerating Blockchain Ticketing
Nextech3D.ai’s planned blockchain ticketing solution-targeted to launch following the close-will be accelerated by Eventdex’s registration and identity stack. Together, the companies intend to deliver:
Fraud and bot resistance: tokenized tickets with provable authenticity and optional KYC/ID verification.
Programmable rights: VIP access, time-based perks, or sponsor benefits embedded into the ticket.
Secondary market economics: on-chain rules to enable royalties and shared economics on verified resales.
Unified attendee journey: from floor plan & sales (Map D) → registration & check-in (Eventdex) → secure, tokenized tickets and analytics in one platform.
Evan Gappelberg, CEO of Nextech3D.ai comments, “Event organizers want one partner who can help them sell more, operate faster, and secure the attendee experience. By adding Eventdex’s registration and on-site badge printing to Map D-and by accelerating our blockchain ticketing launch-we’re moving even faster toward a truly one-stop event operating system.”
Eventdex Co-Founders Durga and Raj comments
“The technology market is at an inflection point since the industrial revolution with upcoming technologies of AI and Blockchain. As engineers, we were always into building products. We have now finally found the match to take our products to the next level and expand the market reach with the leadership of Evan”.
About Eventdex
Eventdex provides event registration, on-site check-in, and badge printing solutions for conferences, trade shows, and corporate events. The company serves 60+ customers and reported approximately $750K in 2024 revenue and ~$500K year-to-date 2025.
About Nextech3D.ai
Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2) is an AI-first technology company focused on event solutions and 3D modeling. Through its Map D platform, Nextech3D.ai powers hundreds of events annually with interactive floor plans, exhibitor management, sponsorships, mobile apps, and ticketing. The Company also delivers AI-powered 3D modeling and spatial computing solutions at scale for major retailers and platforms.
Evan Gappelberg /CEO and Director 866-ARITIZE (274-8493)
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of applicable securities laws, including statements regarding the proposed acquisition of Eventdex, the anticipated timing and consideration, the Company’s blockchain ticketing solution and launch timing, expected benefits and synergies, product integrations, and growth opportunities. Forward-looking statements are based on assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. There can be no assurance that the proposed transaction will be completed as anticipated or at all. Nextech3D.ai disclaims any obligation to update forward-looking statements except as required by law.
Forward-looking Statements The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the completion of the transaction are subject to known and unknown risks, uncertainties and other factors. There can be no assurance that such statements will prove to be accurate, as future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Nextech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws
Expanding the Scalability of High-Voltage Marine Propulsion at FLIBS 2025
FORT LAUDERDALE, FLORIDA / ACCESS Newswire / September 30, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”), a technology-driven marine company specializing in high-voltage electric propulsion systems, together with Sterk Boats, a German performance boatbuilder, today announced the world debut of the first dual application of the E-Motion™ 180E electric marine powertrain system. The premium Sterk 31, launching to market as the Sterk 31e,will be revealed in-water at Bahia Mar G Dock during the 2025 Fort Lauderdale International Boat Show (FLIBS) Oct. 29 – Nov. 02, 2025.
This unveiling marks a defining milestone in the evolution of the E-Motion™ platform. Building on Vision Marine’s April 16, 2025 announcement of hull optimization for electric propulsion, the collaboration has advanced to a fully realized, consumer-ready integration. A premium German-engineered performance vessel, the Sterk 31 was custom adapted by a joint effort of both company engineering teams, with Vision Marine completing the outfitting with two E-Motion™ 180E high-voltage electric outboards, powered by a battery system totalling more than 170 kWh.
Sterk 31E powered by Twin E-Motion 180E – Rendering
“This unveiling at FLIBS represents not only a milestone for Vision Marine, but also for the entire boating industry,” said Alexandre Mongeon, Co-Founder and CEO of Vision Marine. “It demonstrates the scalability and versatility of our E-Motion™ technology, showing its ability to power larger and more demanding classes of recreational boats. This achievement lays the groundwork for future integrations across an even wider range of powerboat platforms.”
Milan Sterk, CEO of Sterk Boats, added: “The Sterk 31 was designed from the outset as a high-performance platform, and working with Vision Marine we have proven that premium German design can be seamlessly matched with advanced high-voltage propulsion. This integration demonstrates how electric power can meet the expectations of demanding boaters, and we are proud to debut it at FLIBS.”
The Sterk 31e dual integration expands Vision Marine’s portfolio of 24 completed integrations of the E-Motion™ 180E system across multiple recreational boating platforms, underscoring its unmatched expertise. By anchoring this world debut at FLIBS, Vision Marine highlights its dual role as both a technology enabler for boatbuilders and a direct-to-consumer innovator through Nautical Ventures, the Boating Industry Top Hundred 2024 #1 U.S. dealership network.
About Sterk Boats
STERK Yachts is a premium boat manufacturer known for blending modern design, high-performance engineering, and sustainable innovation. Based in Germany, STERK Yachts is dedicated to redefining the boating experience by integrating cutting-edge technology with meticulous craftsmanship. The company offers a range of high-quality, precision-built boats that cater to both luxury and performance-driven customers.
Vision Marine Technologies Inc. (NASDAQ:VMAR) is a disruptive marine company focused on delivering premium experiences across electric and internal combustion engine segments. The Company industrialized the first 180 horsepower high-voltage electric outboard powertrain, the E-Motion™ 180E, integrated in 24 different applications across recreational boating platforms. Vision Marine has also acquired Nautical Ventures, the Boating Industry Top 100’s #1 ranked U.S. dealership network, creating North America’s first vertically integrated marine technology and retail platform.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, integration, performance, and anticipated debut of the Sterk 31 twin-engine electric boat, as well as broader commercialization plans. These statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties. Actual results may differ materially. Vision Marine disclaims any obligation to update these forward-looking statements, except as required by law.
Investor Relations Contact Bruce Nurse (303) 919-2913 bn@v-mti.com
Swarm Chorus™ combines machine learning insights and expert systems, empowering facility teams to streamline HVAC service operations directly from their desktops, mitigating the need for multiple application triage.
SAN MARCOS, CA / ACCESS Newswire / September 30, 2025 / Encycle Technologies, Inc., the leader in artificial intelligence and data analytics for commercial HVAC management, announced the release of Swarm Chorus™, a powerful new application that brings machine learning workflow orchestration directly to facilities teams desktops.
Seamlessly integrated with Swarm Sentinel™ into multiple work order management systems, Swarm Chorus transforms how facility teams receive, triage, and dispatch HVAC maintenance across entire building portfolios.
By combining machine learning and expert systems with actionable operational insights, Swarm Chorus delivers fully integrated fault-to-resolution workflows-directly within desktop environments. This revolutionary tool empowers users to confidently prioritize and dispatch HVAC issues, optimizing truck rolls, improving system uptime and budget spend with every service ticket.
Swarm Chorus drives efficient and accurate dispatch decisions for customers within a familiar and convenient interface, unlocking:
Portfolio-Wide Dispatch Optimization
Intelligent Triage Prioritization
Streamlined Maintenance Workflows
Seamless Desktop Integration
Closed-Loop Ticket Execution
Circumvent Comfort Call Noise
“Swarm Chorus delivers for facility teams, what sales technologies have for years delivered to sales managers to keep sales teams fixed on target,” said Ana-Paula Issa, CEO of Encycle. “This technology represents a major leap forward in helping facilities unlock new levels of operational efficiency through automation, insight, and streamlined execution. Gone are the days of chasing hot calls, welcome to the days of organized, racked and stacked workflow, that reduces spending and increases up time.”
Swarm Chorus is the newest innovation added to Encycle’s holistic HVAC management solutions suite, empowering building owners and operators to advance HVAC resiliency by enabling proactive maintenance activities, which improves operational outcomes and prolongs system lifespan.
Swarm Chorus redefines service execution with easy-to-use, scalable tools to improve workflow orchestration. Whether you’re prioritizing a critical failure or scheduling preventative maintenance, Swarm Chorus is built to copilot facility management, ensuring precision in every dispatch decision through better data intelligence.
For more information about Swarm Chorus or to schedule a demo to learn how it improves workflow orchestration, please visit encycle.com or call 1-855-875-4031.
About Encycle:
Deploying autonomous intelligence and analytics, Encycle improves commercial HVAC management, energy efficiency and building comfort to reduce operating costs and carbon footprint. As the only utility-endorsed HVAC optimization software, our patented machine learning solutions seamlessly integrate into maintenance workflows. Encycle enables multi-site commercial and industrial companies to maximize efficiency and reach sustainability goals by improving energy use and budgetary spend decisions. For more information about Encycle, visit encycle.com or follow the company on LinkedIn.
VANCOUVER, BC / ACCESS Newswire / September 30, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec” or the “Company”) is pleased to note today’s press release by HyProMag USA, LLC (“HyProMag USA”), its U.S.-based joint venture rare earth permanent magnet recycling and manufacturing company.
HyProMag USA announced it has purchased three skid-mounted Inserma Anoia S.L (“Inserma”) magnet and Printed Circuit Board (“PCB”) separation units. The Inserma and PCB units can be co-located at hyperscale data centers, shredding, recycling or HyProMag facilities. These Inserma units rapidly remove (at <2 seconds per hard disk drive ("HDD")) the voice coil motor ("VCM") containing the rare earth magnet, providing a highly concentrated feed for subsequent Hydrogen Processing of Magnet Scrap ("HPMS") by HyProMag USA at the Texas facility. The technology package will further complete the separation and removal of the PCB, which contains precious metals, for recycling and sale. The three units will be located and operated by Intelligent Lifecycle Solutions, LLC ("ILS") as it continues stockpiling of feedstock for the Fort Worth facility.
Julian Treger, Chief Executive of CoTec commented: “We are very excited to see the rapid development of the Inserma partnership. Pre-processing technologies are a key enabler and competitive advantage for HyProMag USA as it progresses with the purchase of feedstock. The purchase of these Inserma units is the start of the roll-out of pre-processing technologies to support feedstock suppliers for our magnet recycling and manufacturing facilities. The Company is continuing to progress its discussions with the rapidly expanding hyperscale data center providers and offers a closed loop and secure recycling network within the United States at the lowest cost and lowest carbon footprint. Furthermore, the batch process design of the Texas facility with separate individual feedstock waste streams supports consistent finished grades of magnets and blocks.
For further information, please refer to HyProMag USA’s press release, available at: www.hypromagusa.com
About HyProMag USA
HyProMag USA LLC is owned 50:50 by CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec”) and HyProMag Limited. HyProMag Limited is 100 percent owned by Maginito Limited which is owned on a 79.4/20.6 percent basis by Mkango Resources Ltd. (AIM/TSXV:MKA) and CoTec.
About CoTec
CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) is redefining the future of resource extraction and recycling. Focused on rare earth magnets and strategic materials, CoTec integrates breakthrough technologies with strategic assets to unlock secure, sustainable, and low-cost supply chains for the United States and its allies.
CoTec’s mission is clear: accelerate the energy transition while strengthening U.S. economic and national security. By investing in and deploying disruptive technologies, the Company delivers capital-efficient, scalable solutions that transform marginal assets, tailings, waste streams, and recycled products into high-value critical minerals.
From its HyProMag USA magnet recycling joint venture in Texas, to iron tailings reprocessing in Québec, to next-generation copper and iron solutions backed by global majors, CoTec is building a diversified portfolio with long-term growth, rapid cash flow potential, and high barriers to entry. The result is a game-changing platform at the intersection of technology, sustainability, and strategic materials.
Statements in this press release regarding the Company and its investments which are not historical facts are “forward-looking statements” which involve risks and uncertainties, including statements relating to the Company’s interest in and the proposed expansion of HyProMag USA and management’s expectations with respect to its current and potential future investments, including HyProMag USA, and the benefits to the Company which may be implied from such statements. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements, due to known and unknown risks and uncertainties affecting the Company, including but not limited to resource and reserve risks; environmental risks and costs; labor costs and shortages; uncertain supply and price fluctuations in materials; increases in energy costs; labor disputes and work stoppages; leasing costs and the availability of equipment; heavy equipment demand and availability; contractor and subcontractor performance issues; worksite safety issues; project delays and cost overruns; extreme weather conditions; and social and transport disruptions. For further details regarding risks and uncertainties facing the Company please refer to “Risk Factors” in the Company’s filing statement dated April 6, 2022, a copy of which may be found under the Company’s SEDAR profile at www.sedar.com. The Company assumes no responsibility to update forward-looking statements in this press release except as required by law. Readers should not place undue reliance on the forward-looking statements and information contained in this news release and are encouraged to read the Company’s continuous disclosure documents which are available on SEDAR at www.sedarplus.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments
SEATTLE, WASHINGTON / ACCESS Newswire / October 1, 2025 / The Cancer AI Alliance (CAIA) – a research collaboration of top cancer centers – today announced the first scalable platform using federated learning for cancer research.
Federated learning graphic An overview of the federated learning process.
CAIA is comprised of National Cancer Institute-designated cancer centers Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins with financial and technical support from technology industry leaders Amazon Web Services (AWS), Deloitte, Ai2 (Allen Institute for AI), Google, Microsoft, NVIDIA and Slalom.
The platform serves as the technological foundation of CAIA’s aim to save more lives by enabling researchers and clinicians to train AI models that learn from participating cancer centers’ millions of clinical data points while maintaining data security, privacy and adherence to regulatory and ethical standards.
“We are at an urgent inflection point in both cancer research and AI, and this platform enables us to rise to this moment by rapidly advancing cancer research, treatments and care,” said Jeff Leek, PhD, vice president and chief data officer at Fred Hutch and holder of the J. Orin Edson Foundation Endowed Chair.
“Currently, it takes years to uncover new insights that can be translated into better treatments and care, but this platform will accelerate the pace of breakthrough discoveries by up to tenfold, reducing that time from years to months,” said Leek, who is also the founder and scientific director of CAIA and a member of its steering committee.
“It cannot be overstated how momentous it is that we came together to launch this platform in just one year, and we did it as a unified alliance with a shared mission to eradicate cancer,” said Brian M. Bot, director of the strategic coordinating center for CAIA.
While federated learning – a machine learning method that preserves anonymity of individual data – has been gaining steam for nearly 10 years, adapting the technology for multi-institution use in cancer research has proved elusive due to significant technological, regulatory, patient privacy and data harmonization challenges, as well as the coordination effort necessary to bring together organizations of this scale and complexity.
Development of CAIA’s platform was possible due to an intense focus on collaboration and a drive for collective action across the participating cancer centers and technology companies, resulting in a unified technical, legal and governance structure.
“CAIA represents a strategic shift leveraging collective strength rather than isolation,” said Anaeze Offodile, MD, MPH, chief strategy officer of Memorial Sloan Kettering Cancer Center. “By combining MSK’s clinical expertise with the alliance’s capital, network of technology partners, data and federated framework, we can accelerate meaningful advances in cancer care while upholding the highest standards of security and integrity. Together, we move closer to the shared goal of reducing-and ultimately eliminating-the burden of cancer.”
The federated learning platform works like this: participating cancer centers implement federated learning technology at their institutions, each connecting to a centralized orchestration component of the platform. Using this architecture, AI models travel to each participating cancer center’s secure data to learn from it locally, generating a summary of its learnings without individual clinical data ever leaving institutional firewalls. The insights gained from training the model on each cancer center’s de-identified data are then aggregated centrally to strengthen the AI models to uncover patterns, maximizing the value of the collective knowledge base.
Enabling researchers to develop models on data from multiple cancer centers through a collaborative, federated learning ecosystem creates a paradigm shift from solving problems in isolation to solving them together. More importantly, these updated AI models could significantly improve health outcomes for cancer patients by revealing trends across more diverse populations and rare cancers.
“CAIA will enable unprecedented exploration of AI models for cancer patient data, through a privacy-aware technical framework and a collaborative research alliance,” said Alexis Battle, PhD, professor of biomedical engineering and computer science, and director of the Malone Center for Engineering in Healthcare, and director for Research Strategy and Partnerships, Data Science and AI Institute at the Johns Hopkins Whiting School of Engineering.
“This could serve as a model for every cancer center in the country to join CAIA in this collaborative effort to unlock innovation in cancer care,” continued Vasan Yegnasubramanian, MD, PhD, professor of oncology, pathology, and radiation oncology and molecular radiation sciences at the Johns Hopkins Kimmel Cancer Center and director of inHealth Precision Medicine at Johns Hopkins Medicine. Battle and Yegnasubramanian are members of the steering committee for CAIA.
Eight unique projects are being launched by researchers across the participating cancer centers. These initial projects aim to tackle some of oncology’s most persistent challenges, from predicting treatment response to identifying novel biomarkers and analyzing rare cancer trends. The projects use the federated learning platform and structured, de-identified data housed securely by participating cancer centers, which collectively provides a diverse and representative foundation of over 1 million patients for modeling and analysis.
The platform’s true power, however, lies in its potential to scale up. Over the next year, CAIA plans to enable dozens of research models and add more participants to the alliance.
“With the launch of CAIA we have laid a critical foundation in the effort to accelerate new discoveries and the combined data from our cancer centers can now power these innovative AI models. We are excited to share these models with research centers across the nation and exponentially expand access to the data that will drive progress toward better diagnosis, treatment and outcomes for cancer patients everywhere,” said Eliezer Van Allen, MD, Chandra Nohria Family Chair for AI in Cancer Research at Dana-Farber Cancer Institute.
# # #
Additional CAIA collaborator quotes
“AWS is immensely proud to help power this industry-first collaboration with our cloud technology and LLM platforms, in support of CAIA’s mission to transform cancer research and care,” said Dr. Angela Shippy, Senior Physician Executive and Clinical Innovation Lead at Amazon Web Services. “Collaboration often leads to discovery, and I’m eager to see what medical breakthroughs come from the collective expertise of these world-class cancer centers and global technology leaders.”
“At Deloitte, we believe collaboration drives progress,” said Jason Girzadas, CEO of Deloitte US. “CAIA brings together leaders across industries to address one of the world’s most critical health challenges. The unprecedented speed of developing and delivering CAIA’s platform is made possible through each individual group driving toward this common goal, and Deloitte is proud to bring AI and strategy expertise to the Alliance.”
“We are proud to be part of this effort to bring the power of AI to the complex problem of cancer research,” said Ali Farhadi, CEO of Ai2. “CAIA’s ability to bring together cancer centers in a collaborative effort with our state of the art AI tools is a powerful combination that will accelerate scientific progress and save lives. It’s been incredible to see our tools in the hands of oncologists and researchers, where their early efforts have already demonstrated incredible potential to unlock discoveries that could reshape healthcare and deliver life-changing outcomes for patients.”
“Google is honored to continue to partner with the Cancer AI Alliance,” said Reymund Dumlao, Director, State and Local Government and Education, Google Public Sector. “This groundbreaking initiative represents a pivotal moment in our collective pursuit to eradicate cancer. By integrating advanced federated AI technologies with the expertise and data resources of leading cancer centers, we are establishing a secure, scalable platform designed to accelerate scientific discovery. This collaborative ecosystem will enable a unified effort against cancer, transforming research methods and expediting the delivery of innovative treatments to patients globally.”
“The collaborative work that CAIA has done will revolutionize how medical research is done, accelerate scientific discovery, and save lives,” said Dr. William Weeks, Director of Health, Microsoft AI for Good Lab.
“At Slalom, we see the future of health as being the convergence of technology, data, and strategy to build better tomorrows for all,” said Brenda Young, managing director at Slalom. “CAIA demonstrates how collaboration between leading cancer centers and technology partners can unlock new insights and reshape the use of Data & AI to diagnose, treat, and prevent cancer. We look forward to our continued partnership as we pave the way for transformative breakthroughs in health.”
Media Contact: Molly McElroy and Christina VerHeul media@fredhutch.org 206-667-2210
About the Cancer AI Alliance (CAIA)
The Cancer AI Alliance (CAIA) is comprised of the nation’s top cancer centers with support from technology industry leaders. CAIA aims to accelerate cancer discovery and treatment. Since its founding in 2024, CAIA has secured $65M in financial and technical support. Through this unprecedented collaboration, CAIA launched the first scalable, multi-cloud federated learning platform for cancer research, which enables researchers to train AI models on diverse, multi-institutional clinical data while maintaining data security and privacy. By combining the collective knowledge of its members, CAIA is on a mission to redefine the cancer research landscape.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.
Dana-Farber is the only hospital nationwide with a top 3 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.
Fred Hutch Cancer Center
Fred Hutch Cancer Center unites individualized care and advanced research to provide the latest cancer treatment options while accelerating discoveries that prevent, treat and cure cancer and infectious diseases worldwide.
Based in Seattle, Fred Hutch is an independent, nonprofit organization and the only National Cancer Institute-designated cancer center in Washington. We have earned a global reputation for our track record of discoveries in cancer, infectious disease and basic research, including important advances in bone marrow transplantation, immunotherapy, HIV/AIDS prevention and COVID-19 vaccines. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services. Fred Hutch also serves as UW Medicine’s cancer program.
Johns Hopkins University
As the nation’s first research university, Johns Hopkins’ mission is to foster cutting-edge research and innovation, to educate its students and cultivate their capacity for lifelong learning, and to bring thebenefits of discovery to the world through its 10 world-renowned schools, and numerous institutes and centers.
Sidney Kimmel Comprehensive Cancer Center Since our founding more than 50 years ago, our medical pioneers led the way to understanding cancer through impactful research, developing novel therapies, and attending to the complex needs of patients. Our experts mapped the genomic blueprints for cancer, deciphered the epigenome, discovered ways to make the immune system fight cancer, eliminated the need for perfect matches in bone marrow transplant, pioneered life-saving surgeries, and brought proton therapy and other advanced technologies in radiation therapy.
Whiting School of Engineering We advance data- and science-driven engineering discovery, innovation, and systems applications to help everyone live longer and healthier lives and empower communities and society to thrive even in extreme environments. With more than 26 research centers and institutes – including the Data Science and AI Institute – and through strong community, university, and industry partnerships, Hopkins Engineering is a driving force in the future of technology, health care, and engineering education.
Memorial Sloan Kettering Cancer Center
The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years. www.mskcc.org
Contact Information
Christina VerHeul Associate Vice President, Communications media@fredhutch.org (206) 667-2210
Early Patient Feedback Points to Clearer Understanding of Results and Smoother Treatment Planning
GRAND RAPIDS, MICHIGAN / ACCESS Newswire / October 1, 2025 / Quintessence Psychiatry, a telepsychiatry practice led by Nona Kocher, MPH, MD, has adopted Mentavi Health‘s asynchronous Diagnostic Evaluation to offer patients a scientifically rigorous, accessible alternative to full neuropsychological testing. The Mentavi Diagnostic Evaluation is clinically validated (and now peer-reviewed and published in the The Journal of Clinical Psychiatry*) for the diagnosis of ADHD in adults.
Quintessence Psychiatry previously referred ADHD inquiries to external neuropsychology providers – a process that can involve weeks to months of waiting and hundreds of dollars in testing costs for a broad battery of tests many patients don’t need. Early experiences at Quintessence show patients can complete the self-directed evaluation at their convenience (often at home) and return to the clinic with a report reviewed by a licensed psychologist to guide treatment conversations.
“Mentavi gives my patients a focused, evidence-based ADHD evaluation at a price and speed they can actually use,” said Dr. Nona Kocher, psychiatrist and founder of Quintessence Psychiatry. “It adds rigor to my workflow and helps patients understand what the findings mean, so we can move forward with an informed plan rather than sending them into a lengthy outside testing queue.”
In the initial phase of adoption, three patients have completed the evaluation, with positive feedback on the clarity of the results and visuals. Patients typically review the Mentavi report with Dr. Kocher at a follow-up visit to discuss how ADHD symptoms may be affecting daily life and to consider therapy and/or medication options. “The report graphics make it easier for patients to grasp their results at a glance, which improves shared decision making,” Dr. Kocher added.
Beyond speed and accessibility, the Mentavi Diagnostic Evaluation integrates cleanly into Quintessence’s care model, which emphasizes applying modern, science-based methods – including, when appropriate, pharmacogenetic testing – to reduce trial and error in treatment selection.
“We are pleased that our validated diagnostic approach can serve Quintessence Psychiatry by removing barriers to timely access to care for their patients. This is what our approach was designed for,” said Keith Brophy, CEO of Mentavi Health.
“Clinicians like Dr. Kocher tell us Mentavi helps them triage ADHD inquiries efficiently and focus their time where it matters most – on individualized care,” said Mentavi Health Chief Medical Officer Barry K. Herman, M.D., MMM. “We’re pleased to support private practices with an evaluation that is clinically validated, rigorous, patient-friendly, and easy to fold into existing workflows.”
Quintessence intends to continue offering the Mentavi Diagnostic Evaluation for appropriate ADHD cases and to gather ongoing patient feedback to inform clinical workflows.
* Peer‑reviewed validation: Results of Mentavi’s diagnostic validation study were published in The Journal of Clinical Psychiatry on September 8, 2025 (J Clin Psychiatry 2025;86(3):25m15846; doi:10.4088/JCP.25m15846).
About Quintessence Psychiatry
Quintessence Psychiatry is a patient-centered telepsychiatry practice led by Nona Kocher, MD, offering comprehensive evaluations, medication management, and individualized care plans. The practice integrates modern, evidence-based methods to help patients move from assessment to actionable next steps. For more information, visit quintessencepsychiatry.com.
About Mentavi Health
Established as ADHD Online in 2018, Mentavi Health has evolved to encompass a broader range of mental health services. With the mission to make high-quality ADHD assessments accessible to all, Mentavi has grown to address not only ADHD but also the most common related mental health conditions. The nationwide Mentavi Diagnostic Evaluation and various treatment options showcase the company’s commitment to providing comprehensive, accessible, and compliant online mental health care, grounded in clinical validation and trust. For more information, visit mentavi.com.
HAYWARD, CALIFORNIA / ACCESS Newswire / October 1, 2025 / Biolog, Inc., a trusted leader in microbial identification and testing, today announced its new Foodborne Pathogen Testing Service, out of it’s Newark, Delaware location, expanding its portfolio to include ISO-certified molecular assays that safeguard food safety and support regulatory compliance for food producers of all sizes.
Available Foodborne Pathogen Testing
The new service delivers rapid, scientifically validated detection across various matrices for the five most common foodborne pathogens: E. coli O157 (including H7), Salmonella, Listeria monocytogenes, Campylobacter, and Cronobacter.
“We’ve heard from many of our customers in food manufacturing that they are under intense pressure to ensure safety while keeping production on track,” said Robert Wicke, CEO at Biolog. “As their trusted microbial testing expert, we are thrilled to be able to offer this new service that helps them protect their brands, avoid costly recalls, and stay ahead of evolving regulatory requirements.”
With 40+ years of microbial expertise, Biolog Lab Services delivers a best-in-class combination of speed and dependability in microbial testing services. Customers benefit from reliable results in as little as three days, backed by AOAC, AFNOR validations, and ISO 17025 certification, ensuring adherence to the strictest global standards. The service offers high sensitivity and specificity at a competitive price point, while being grounded in USDA-approved and FDA-endorsed molecular science.
Biolog’s strategic proximity to major agricultural hubs gives regional produce, beef, and poultry producers a critical edge. By offering certified results in days rather than weeks, Biolog enables these producers to stay compliant, reduce scrap costs, and make confident decisions faster.
Biolog’s expansion into foodborne pathogen testing reinforces its role as a comprehensive partner for microbial testing solutions, delivering the expertise, speed, and dependability food producers need.
To learn more about Foodborne Pathogen Testing, request a quote, or explore Biolog’s comprehensive microbial testing portfolio, please visit www.biolog.com.
About Biolog Biolog has the tools, services, and support to provide comprehensive cellular characterization and multi-omic identification for thousands of bacteria, yeast, and fungal species. Our products enable the growth and phenotypic profiling of microbial and mammalian cells for a wide range of applications, including pre-reduced media and gloveless chambers that support culturing organisms under strictly anaerobic conditions. Learn more at biolog.com.
Contact Information John Proctor, Ph.D. CCO jproctor@biolog.com (408)306-0414
GUELPH, ON / ACCESS Newswire / October 1, 2025 / Six Star Travel, a boutique agency specializing in travel planning, has been awarded the 2026 Consumer Choice Award in the Travel Agencies category for Guelph. Known for its expertise, personalized service, and commitment to excellence, Six Star Travel has built a reputation as a trusted partner for travellers seeking exceptional experiences.
Founded by travel professional Steven A. Faehrmann, Six Star Travel creates customized solutions designed to meet the needs of discerning clients. The agency offers a full spectrum of services, including cruises, resorts, hotels, expedition travel, and bespoke tours.
“Our role is to simplify travel planning while elevating the experience,” says Steven Faehrmann. “We focus on details that matter, from carefully selected accommodations to unique excursions, ensuring every client enjoys a journey that is thoughtfully curated and stress-free.”
A Commitment to Value and Service
As a member of Ensemble, Six Star Travel leverages exclusive relationships with leading suppliers worldwide. This allows clients to benefit from added value such as complimentary room upgrades, shipboard credits, and private tours. While specializing in premium travel, the agency’s focus on maximizing value ensures high-quality service at competitive rates.
Recognition and Client Trust
This marks the third consecutive year that Six Star Travel has been recognized with the Consumer Choice Award, reflecting its consistent commitment to excellence. Its 5-star Google reviews further highlight the trust and appreciation expressed by clients. With nearly two decades of experience, Steven’s passion for travel has taken him to more than 51 countries and over 700 cities worldwide – knowledge he draws on to deliver unique insights and advantages to every client journey.
Trusted by the Community
Located in Guelph, Six Star Travel has earned the loyalty of its clients by prioritizing reliability, professionalism, and personalized care. The agency is committed to supporting travellers throughout their journey – from consultation and booking to assistance during travel and follow-up upon return. Clients consistently commend the agency for its attention to detail, proactive problem-solving, and ability to anticipate needs. This dedication has helped Six Star Travel build lasting relationships with both new and returning customers in the Guelph region.
“Our success is grounded in the trust of our clients,” adds Faehrmann. “Receiving this recognition is an honour and a reflection of the service standard we strive to uphold every day.”
About Six Star Travel Six Star Travel is a boutique travel agency based in Guelph, Ontario. Led by founder Steven A. Faehrmann, the agency provides a full range of services including cruises, resorts, tours, and expedition travel. With a focus on integrity, value, and client satisfaction, Six Star Travel delivers exceptional service and unforgettable journeys. To learn more, visit www.sixstartravel.ca.
About Consumer Choice Award Since 1987, Consumer Choice Award has been recognizing and promoting business excellence across North America. Through a rigorous selection process, only the most outstanding businesses in each category earn this prestigious recognition. Learn more at www.ccaward.com
